In the third quarter, 18 pharmaceutical companies listed, who is the market value of hundreds of billions of "potential stocks"?

A total of 18 pharmaceutical companies entered the A-share market in the third quarter, and as of the close of trading on October 24, only one with a market capitalization of more than 50 billion yuan, huada gene, market value: 64.37 billion yuan. There are five companies with a market value of 10 billion to 50 billion yuan, of which Dasinlin has a market value of 17.36 billion yuan and Dabo Medical has a market value of 16.84 billion yuan.
market value: 17.36 billion yuan
the time flies, in a blink of an eye, 2017 has passed a large part. According to statistics, a total of 18 pharmaceutical companies successfully landed A-shares in the third quarter. Among them, known as the "gene industry Tencent" Huada gene, the fourth listed drugstore chain Dasanlin and domestic orthopaedic implants in the field of medical supplies, one of the leading enterprises, Dabo Medical, these three combined nearly 100 billion market value.
18 pharmaceutical companies listed in the third quarter
a total of 18 pharmaceutical companies landed in the A-share market in the third quarter, as of the close of October 24, the market value of more than 50 billion yuan only one, Huada gene; 10 billion to 50 billion yuan has 5, DasinLin, Dabo Medical, Jinyuan Medicine, Chenxin Pharmaceuticals and Jianyou shares; There are 12 companies under 10 billion yuan, such as Ha Sanlian, Ki egg biology, Ed biology and Weixinkang.
data show that huada gene after the listing of the stock price soared more than 11 times, is the third quarter of the only listed pharmaceutical companies share price of more than 100 yuan, its market value is close to 70 billion yuan. Currently ranked seventh in the industry, it is expected to achieve a market value of 100 billion yuan in the future. 3 pharmaceutical companies combined nearly 100 billion market value NO.1 Huada Gene
market value: 64.37 billion yuan
In July this year, Huada Gene officially landed in A-shares, its main business is through genetic testing and other means, for medical institutions, scientific research institutions, enterprises and institutions to provide genomics diagnosis and research services. The main products include basic research and clinical application services for reproductive health, basic scientific research services, basic research and clinical application services for complex diseases, and drug basic research and clinical application services.
In the first half of 2017, Huada Gene signed a comprehensive cooperation agreement with a number of hospitals, and signed strategic cooperation agreements with the governments of Fuyang City, Shandong Province, Qingdao City, Shandong Province, Tai'an City, Shandong Province, covering non-invasional prenatal genetic testing, neonatal genetic testing, HPV gene testing, rapid detection of pathogenic microorganisms and other projects. Tumor genetic testing services and more than 150 hospitals in China have stable business cooperation. HLA business has more than 110 hospitals and research institutes, 20 bone marrow and cord blood bank at all levels have a stable business cooperation, testing samples of more than 446,000 cases. The company's business scope has covered more than 100 countries and regions around the world, including 31 provinces and autonomous regions of more than 2,000 scientific research institutions and more than 2,300 medical institutions, including more than 300 hospitals; There are more than 3,000 overseas medical and scientific research institutions working together in Europe, the Americas and Oceania.
addition, Huada Gene has always attached importance to research and development of new types of services, the first half of the research and development investment of 7095.09 million yuan. The company has carried out extensive research and development in the fields of genetic deafness, pre-pregnancy genetic diseases, non-invasive prenatal testing, tumors and other diagnostic services, as well as basic scientific research.
October 13, Huada Gene released its first three-quarter earnings forecast, forecasting a net profit of 30 million to 320 million yuan, up 16.69% to 24.47% year-on-year. Performance growth was mainly due to the company's overall business continued the growth trend in the first half of the year, reproductive health, basic research, complex diseases and drug research and development business continued to grow year-on-year.
NO.2 Dasanlin
Market value: 17.36 billion yuan
Dasanlin has been focusing on Chinese and Western medicine, ginseng tonic herbs and Chinese medicine tablets, health care products, medical equipment and other commodities of the direct chain retail business, especially in the field of ginseng tonic herbs formed an independent brand-oriented, covering high and low grade products, to meet the needs of different consumer groups of business characteristics, is the country's leading large-scale pharmaceutical retail enterprises. In the first half of the year, operating income was RMB351.19 million, up 18.65% YoY, and net profit attributable to shareholders of the parent company was RMB248.42 million, up 14.45% YoY.
's business strategy is to direct chain stores as the core, in-depth development and consolidation of the South China market on the basis of continuous radiation to surrounding provinces and cities. As of the first half of 2017, the company has established a total of 2,625 direct chain stores covering Guangdong, Guangxi, Henan, Fujian, Jiangxi, Zhejiang and other provinces, with 232 new stores. In addition to brick-and-mortar stores, actively expand online sales channels. Improve online sales capabilities and customer service through the self-built Dasanlin Online Mall and other e-commerce platforms.
the second half of this year, Dasinlin will strengthen the network of stores near the hospital, while accelerating the pace of searching for mergers and acquisitions cooperation standards, improve the network layout, especially in areas where there are already spots. Continuously enhance the competitiveness of commodities, continue to optimize the product structure, accelerate product sales, the rapid introduction of market potential varieties. In addition, actively do a good job in the preparation of medical reform policy, to create a professional DTP/DTC pharmacy, actively communicate with associated pharmacies, and medical institutions to communicate prescription transfer construction.
NO.3 Dabo Medical
Market Value: 16.84 billion yuan
Dabo Medical's main business is the production, research and development and sales of medical high-value supplies, the main products include orthopaedic trauma implant supplies, spinal implant supplies and neurosurgery implant supplies, accounting for more than 90% of the company's operating income. After years of technical research and development and accumulation, the current Dabo Medical product registration has covered orthopaedic trauma, spine, neurosurgery and other fields a total of about 15,400 specifications of various types of consumables products.
It is worth mentioning that Dabo Medical has developed and upgraded some common adaptive and original products in the field of orthopaedics, including: pre-filled artificial bone, absorbable interface screws, vitamin E polyethylene lining in hip replacement, HA-coated bone needle, thoracic lumbar elastic internal fixation system, etc. In the future, we plan to expand the field of medical high-value consumables such as craniofacial surgery, general surgery, minimally invasive surgery and dental, while increasing the size and category of orthopaedic products such as artificial joints and sports medicine, which will be an important driver of the company's future revenue growth.
expected first three quarters of operating income of 42.77571 million - 462.2537 million yuan, an increase of 24%-34% YoY; Net profit attributable to the parent company is expected to be RMB204.7189 million-222.6766 million, an increase of 14%-24% YoY. (Minenet)